Tirzepatide

Heart failure (HF) is associated with high morbidity and mortality. HF with preserved left ventricular ejection fraction (HF-pEF) accounts for up to 50% of all HF cases, being the most common in elderly patients. In addition, these subjects frequentl…

OBJECTIVES: To investigate the clinical characteristics of weight loss drugs (WLDs) users in Norway. DESIGN: Nested population-based case-control study. SETTING: Nationwide healthcare registries with data on dispensed medications and healthcare diagn…

GIM/FP/GP:[Formula: see text] Cardiology:[Formula: see text] Endocrinology:[Formula: see text].

OBJECTIVE: A majority of adults with type 1 diabetes (T1D) are overweight (OW) or obese (OB) and often struggle to reach glycemic targets. Tirzepatide, a dual-incretin approved for type 2 diabetes (T2D) and OW/OB, has been shown to improve glucose co…

PURPOSE: To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2026 in the United States, with a focus on the nonfederal hospital and clinic sec…

The development of scalable and efficient manufacturing of high-volume complex synthetic peptides and proteins, like tirzepatide (TZP, 1), faces major hurdles due to the limitations of traditional Solid Phase Peptide Synthesis (SPPS) and Liquid Phase…

Tirzepatide has been approved for the management of obesity, obstructive sleep apnea, and type 2 diabetes mellitus; while gastrointestinal side effects are commonly seen, ischemic colitis has been only rarely described. We present the case of a 32-ye…

Over the recent years, there has been a notable surge in consumer demand for rapid and effective weight-loss pharmaceuticals that are also capable of managing type 2 diabetes. Owing to their exceptional efficacy, GLP-1 receptor agonists, including Ti…

The rapid proliferation of anti-obesity medications (AOMs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonist tirzepatide, and non-incretin agents, including orl…

AIMS: Pharmacotherapy for metabolic associated steatotic liver disease (MASLD) is reserved for steatohepatitis (MASH) with moderate Fibrosis Grades 2-3. Randomised controlled trials (RCT) of clinically available medications with biopsy data were eval…

BACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive disease continuum linking metabolic risk factors with cardiovascular and kidney disease. Patients in early CKM stages (stages 1-2) represent a critical therapeutic wi…

OBJECTIVE: Ketoacidosis is a critical adverse event requiring close clinical monitoring. Based on the Adverse Event Reporting System (FAERS) database of the U.S. Food and Drug Administration (FDA), this study aimed to identify the drugs with the clos…

Skin redundancy after massive weight loss often requires body contouring procedures such as abdominoplasty and mastopexy. Bariatric patients may face higher complication risks due to nutritional deficiencies. However, with proper management, includin…

INTRODUCTION: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are key therapies for type 2 diabetes and obesity, regulating blood glucose by mimicking endogenous GLP-1. Despite efficacy, GLP-1 RAs are associated with adverse reactions across mu…

BACKGROUND: Incretin-based therapies induce substantial weight loss and are widely prescribed; disproportionate losses in fat-free mass (FFM) and skeletal muscle are a concern. PURPOSE: To evaluate body composition changes associated with incretin th…

OBJECTIVES: This study aimed to test whether tirzepatide, a dual GLP-1RA/GIP agonist, approved for weight management, would be associated with lowered serum uric acid (SUA) levels via its weight reduction properties. METHODS: A post hoc analysis of t…